CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Fluticasone Propionate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03926026
NCT03926026Phase 2Completed
CompareCT.gov

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis

Nicox Ophthalmics, Inc.·interventional·Posted Apr 24, 2019·Updated Jun 18, 2023

In Brief

A Phase 2 clinical trial evaluating Fluticasone Propionate and Placebo for Blepharitis. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbations of blepharitis. The study will be performed in two sequential dose escalating cohorts. The study is designed to select the dose(s) of NCX 4251 to advance into the next stage of development, and to assess the safety and tolerability of NCX 4251 Ophthalmic Suspension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 24, 2019
Enrollment StartMar 18, 2019
Primary CompletionOct 21, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.2 years ago

Interventions

Fluticasone Propionatedrug

NCX 4251 Ophthalmic Suspension, 0.1%

Placebodrug

NCX 4251 Ophthalmic Suspension, 0%